E5103

Despite pleas of breast cancer advocates to maintain access to Avastin using gene markers to identify those most likely to benefit, there is little evidence to suggest that the drug company or regulatory experts are considering this strategy.

NCI has outlined changes to its IP policies for collaborative research agreements that would essentially provide industry collaborators with first-option commercial licensing rights for IP arising from studies that make use of pharma companies' proprietary drugs, or samples from patients treated with those drugs.

The New York Times reports that as China invests in science, it also is dealing with research fraud.

In PLOS this week: transcriptome study of a cold-tolerant plant, deep sequencing of clinical influenza A samples, and more.

The Atlantic writes that retrotransposons like BovB have proliferated in a number of genomes.

Researchers have sequenced the genome of a man who lived in China some 40,000 years ago, according to UPI.